A bankruptcy court judge in Delaware has approved the sale of Seattle-based Dendreon’s assets to Valeant Pharmaceuticals International for $495 million.

Share story

A bankruptcy court judge in Delaware has approved the sale of Seattle-based Dendreon’s assets to Valeant Pharmaceuticals International for $495 million.

The final purchase price was raised from the previously announced $400 million to reflect the inclusion of $80 million in Dendreon cash and the assets related to Dendreon’s enteric coated D-3263 hydrochloride product candidate, the company said in a regulatory filing.

The money will go to Dendreon’s secured noteholders, who are owed more than $600 million.